Replaces Prod. #: ALX-270-274
Potent inhibitor of CDK1/cyclin B (IC50=400nM). Also inhibits CDK2/cyclin A (IC50=680nM) , CDK5 (IC50=850nM) and with much less effect other kinases. More recently, kenpaullone has been found to be a useful GSK-3β inhibitor (IC50=23nM). Induces pluripotency in somatic cells when used in combination with reprogramming factors. Increases neurogenesis of human neural progenitor cells through stimulation of Wnt/β-catenin signaling pathway.
Product Details
| Alternative Name: | 9-Bromo-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5H)-one |
| |
| Formula: | C16H11BrN2O |
| |
| MW: | 327.2 |
| |
| CAS: | 142273-20-9 |
| |
| Purity: | ≥98% (TLC) |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | Tan solid. |
| |
| Solubility: | Soluble in DMSO (>25mg/ml); insoluble in water or ethanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J.
371, 199 (2003),
Abstract;
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?: S. Leclerc, et al.; J. Biol. Chem.
276, 251 (2001),
Abstract;
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity: C. Kunick, et al.; Bioorg. Med. Chem. Lett.
10, 567 (2000),
Abstract;
Inhibition of CDKs as a therapeutic modality: E.A. Sausville, et al.; Ann. NY Acad. Sci.
910, 207 (2000),
Abstract;
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25: M. Leost, et al.; Eur. J. Biochem.
267, 5983 (2000),
Abstract;
Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition: R. Gussio; Anticancer Drug Des.
15, 53 (2000),
Abstract;
ATP-site directed inhibitors of cyclin-dependent kinases: N. Gray, et al.; Curr. Med. Chem.
6, 859 (1999),
Abstract;
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases: D.W. Zaharevitz, et al.; Cancer Res.
59, 2566 (1999),
Abstract;
Fused azepinones with antitumor activity: C. Kunick; Curr. Pharm. Des.
5, 181 (1999), (Review),
Abstract;
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity: C. Schultz, et al.; J. Med. Chem.
42, 2909 (1999),
Abstract;
Related Products
